The FDA's April 2026 proposal would end large-scale compounding of semaglutide and tirzepatide. Individual-patient compounding isn't affected, but the supply picture is about to shrink.

Drug ads that name a condition and a brand are banned nearly everywhere in the world. Here's how the US and New Zealand ended up as the two exceptions.

A bottle of melatonin in an American drugstore can pack five to ten milligrams; the same supplement in France is capped under two. The regulatory gap has real consequences for how families use -- and mis-store -- a hormone most people assume is harmless.

The FDA cited Happiest Baby for selling SNOO products without clearance and flagged mold and unsanitary refurbished units, giving the company 15 days to respond.